OBJECTIVES: With multiple recent approvals. substantial progress has been made in the treatment of RCC patients who failed the initial therapy. Recently emerged US oncology value frameworks use heterogeneous methodologies, consider different evidence and target audience. Here we summarize the different approaches and outcomes of National Comprehensive Cancer Network Evidence Blocks (NCCN), American Society of Clinical Oncology Conceptual Framework (ASCO) and Memorial Sloan Kettering Cancer Center DrugAbacus (MSKCC), using examples in 2L-RCC. METHODS: PSE curated oncology database identified six FDA-approved treatments with multiple publications of randomized controlled trials (RCTs) in 2L-RCC: axitinib (AXI), cabozantinib (CAB), everolimus (EVE) lenvatinib+everolimus (LEN+EVE), nivolumab (NIV), sorafenib (SOR). Relevant endpoints from PSE database and 30-day costs derived from GPI pulse (averages sales prices/ wholesaler acquisition costs) were used to calculate ASCO Net Health Benefit (NHB) and MSKCC value price; and compare with NCCN approach. RESULTS: There were significant differences in the assessment of value by frameworks. NCCN assigned higher efficacy and safety score to NIV (4/5), while ASCO NHB was the highest for LEN+EVE (66/130). All regimens had the same NCCN affordability score (2/5) despite >3X monthly costs variations. MSKCC does not include combination therapy nor CAB. For the remainder, the MSKCC price fell below the market price only when $150,000/life year was used for pricing. Using a 20% discount for toxicity and a multiplier of 1.5 for other attributes yielded MSKCC price above the market price for all products accept AXI. CONCLUSIONS: Although there are common themes among frameworks, heterogeneous methodologies and various data considerations lead to significant variability in value judgement and inconsistent recommendations. Further refinement of each framework is ongoing; however, it is clear that in the dynamic environment where growing evidence may change rapidly, a careful review of such evidence and transparent methodology are important to support clinical decision making.